AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

AMPH · NASDAQ · Drug Manufacturers - Specialty & Generic

Amphastar Pharmaceuticals (AMPH)

Maker of technically demanding generic and branded injectable, inhalation, and intranasal drugs.

$24.32

After hours−0.04 (−0.16%)

At close$24.36(−0.49%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	181	178	172	182	189	187	171	174	192	183	171	184
Cost of revenue	72	82	85	87	87	100	85	88	93	97	101	90
Gross profit	108	96	87	95	102	87	85	86	99	86	70	93
	36	42	39	40	45	42	48	44	73	50	57	54
Research & development	17	20	14	18	21	18	20	20	22	23	27	22
	19	22	25	22	24	23	28	24	51	27	30	32
Selling & marketing	6	9	9	9	9	10	12	10	12	10	12	13
General & administrative	13	13	16	13	15	13	16	14	39	16	18	18
Operating income	73	54	48	55	57	45	37	42	25	36	14	40
	−9	−13	−1	−5	−9	−1	−6	−3	−4	−4	−4	−1
Interest income	1	2	3	3	2	2	2	2	2	2	2	2
Interest expense	14	9	9	9	7	6	6	6	6	7	7	7
Other non-operating income	−5	3	−8	−4	3	−5	0	−3	−2	−3	−3	−5
Income before tax	63	41	47	50	48	44	31	39	22	32	10	39
Income tax expense	14	5	4	12	7	6	6	8	4	7	4	8
Net income from continuing operations	49	36	43	38	40	38	25	31	17	24	6	30
Net income	49	36	43	38	40	38	25	31	17	24	6	30
EPS, basic	$1.01	$0.75	$0.90	$0.78	$0.83	$0.78	$0.53	$0.66	$0.38	$0.53	$0.14	$0.69
EPS, diluted	$0.91	$0.68	$0.81	$0.73	$0.78	$0.74	$0.51	$0.64	$0.37	$0.51	$0.14	$0.67
Weighted average shares, basic	49	48	48	49	49	48	48	47	46	46	45	44
Weighted average shares, diluted	54	53	53	52	52	52	50	48	48	47	46	44
EBITDA	91	65	70	73	69	65	52	62	42	55	33	45
Depreciation & amortization	14	14	14	14	14	15	15	16	14	16	16	0
EBIT	77	51	56	59	54	50	37	46	28	39	17	45